Addressing the Challenges of Next-Generation Antibody-Drug Conjugate Medicines

Published on April 4, 2022

Access and leverage deep industry knowledge into some of the key strategies in support appropriate target product profiling for the development of next-generation Antibody-Drug Conjugates (ADCs).

The post Addressing the Challenges of Next-Generation Antibody-Drug Conjugate Medicines appeared first on abzena.

Continue reading on website
Other news

Oligonucleotide ADC Design and Development – An Emerging Field Building on the Success of ADCs in Cancer

April 4, 2022
Create new potential in the ADC oncology space with deep insight and understanding into the innovative field of oligonucleotide bioconjugates,  focusing upon their design, development, analysis and manufacture.The post Oligonucleotide ADC Design and Development – An Emerging Field Building on the Success of ADCs in Cancer appeared first on abzena.

Process Development: Getting from Phase I to III.

April 4, 2022
Learn how to de-risk and accelerate development by understanding the typical points in the CMC development cycle where it is important to prospectively identify where there may be knowledge gaps, and how to identify where compromises and trade-offs are in the process development approach.The post Process Development: Getting from Phase I to III. appeared first on abzena.